Investigation of MiR-21, MiR-32 and MiR-181a/b in terms of Treatment Response in Multiple Myeloma

Introduction/AimMultiple myeloma (MM) is a B-cell neoplasm characterized by the proliferation of clonal malignant plasma cells in the bone marrow. The incidence rate is higher in leukemia and hematologic system comes second after lymphoma among malignant tumors and constitutes about 15% of all haematological cancers. Despite the identification of new drugs such as thalidomide, bortezomib, and lenalidomide, which result in a higher overall response rate and longer life span in MM treatment, MM is still an untreatable disease.MicroRNAs (miRNAs) play a role in critical biological processes such as cell differentiation, apoptosis and cell proliferation in cancer. Recent studies have identified miRNA profiles in human myeloma cell lines and primer patient specimens, and these miRNA expression patterns have been associated with specific genetic anomalies and the patient's surveillance. The aim of this thesis work was to examine that difference in expression levels of the 4 miRNAs (miR-21, miR-32, miR-181a and miR-181b) associated with response to treatment.Material and methodsThe level of expression of (miR-21, miR-32, miR-181a and miR-181b genes) in cells of Multiple Myeloma patients, RNA samples that obtained from whole blood samples of 38 MM patients (pre-treatment and post-treatment) and healthy control groups were investigated the expression pattern of miRNAs using Real-Time PCR technique.Results The comparison of MM group with healthy controls revealed upregulation of 4 miRNAs levels before starting of chemotherapy treatment, and after treatment there were decreased in these levels as response in treatment, but some patients showed non-response effect to treatment. In chemotherapy response group, the length of time free from MM disease was associated with decreased miR-32 Expression levels as a result of treatment response. Conclusion miR-21, miR-32, miR-181a and miR-181b regulate cell differentiation, proliferation, apoptosis and participate in vascular invasion and metastasis of tumor cells. We believe that the inhibition of miR-21, miR-32, miR-181a and miR-181b in future experiments with anticancer drugs, and the investigation of whether drug activity develops if these microRNAs are inhibited can also contribute to both the patient's benefit and the literature

Analysis of the BACE1 and Clusterin Genes Expression Levels in Alzheimer's Disease

Objective: This study aimed to explore the mRNA expressions of the beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) and clusterin (CLU) genes in blood samples of patients with Alzheimer's disease (AD) and healthy subjects

Investigation of MMP-9 rs3918242 and TIMP-2 rs8179090 polymorphisms in renal cell carcinoma tissues

Background: The proteolytic activities of matrix metalloproteinases (MMP), cell surface enzymes degrading extracellular matrix, is inhibited by matrix metalloproteinase tissue inhibitors (TIMP). We aim to detect the effects of MMP-9 rs3918242 and TIMP-2 rs8179090 gene variations in renal cell cancer transformation

The expression levels of miR-655-3p, miR127-5p, miR-369-3p, miR-544a in gastric cancer

Background: Gastric cancer, one of the most common cancers in the world, is a multifactorial disease in which environmental and genetic factors play a role. In our study, we aimed to determine the expression levels of four miRNAs (miR127-5p, miR-544a, miR-369-3p and miR-655-3p) on chromosome 14q32 in gastric cancer

MTHFR C677T and A1298C Gene Polymorphisms in Human Kidney Cancer Tissues

Introduction: The potential effect of 5,10-methylenetetrahydrofolate reductase (MTHFR) on DNA methylation, DNA repair and DNA synthesis has made MTHFR a cancer-inducing gene. In this study, we aimed to evaluate C677T and A1298C gene polymorphisms in kidney cancer

METABOLİK SENDROM KLİNİK PARAMETRELERİNDE SR-BI GEN POLİMORFİZMLERİ ETKİSİNİN ARAŞTIRILMASI

AMAÇ: Metabolik Sendrom (MetS) dünya genelinde giderek yayılan ve çok sayıda insanı etkileyen önemli bir morbidite nedenidir. Yüksek trigliserid (TG) düzeyi ve düşük HDL düzeyi MetS teşhisindeki önemli faktörlerdir. SR-BI’ın ateroskleroz üzerindeki koruyucu etkisi ters kolesterol transportu sürecine katkıda bulunmasıyla gerçekleştirdiği (1) için rs 5888 ve rs 4238001 gen varyantlarının metabolik sendromlu hastaların klinik parametrelerine etkilerini araştırmayı hedefledik. MATERYAL VE METOD: 30-65 yaş aralığında 104 erkek metabolik sendromlu hasta ile metabolik sendrom hikayesi olmayan sağlıklı 100 erkek bireyin bulunduğu kontrol grubundan oluşmaktadır (SU TF Etik Kurul Karar No: 2015/19). Kan örneklerinden DNA izole edilip, saflık tayinleri ve miktarları hesaplandı. SR-BI genine ait ekzon 8’deki C>T (rs5888) değişimi ve ekzon 1’deki C>T (rs4238001) değişimi SNaPshot multipleks sistemi ile incelendi (Tablo 1, 2, 3 ve Şekil 1). Hasta ve kontrol gruplarında genotip ve allel dağılımları istatistiksel analizle (SPSS18) incelendi. BULGULAR: rs4238001 polimorfizminin hastalığa yatkınlık riskini artırdığı, rs5888 polimorfizminin ise etkisinin olmadığı görülmüştür. Hasta grubu rs4238001 genotiplere göre gruplandığında; kilo, vki, bel çevresi, HDL ve trigliserid ölçütlerinin arasında herhangi bir ilişki belirlenememiştir (pkilo=0,952;pVKİ=0,659; pbel çevresi= 0,303; pHDL= 0,622; ptrigliserid= 0,661) (Tablo 4). TARTIŞMA: Popülasyonumuzda rs4238001 ve HDL ya da diğer klinik veriler arasında bir ilişkiye rastlanmamıştır

Investigation of JAM-A (rs790056) and LFA-1 (rs8058823) gene variants in Turkish colorectal cancer patients

Background/Aims: Lymphocyte function-associated antigen 1 (LFA-1) is a transmembrane glycoprotein expressed on the surface of leukocytes and containing the binding domain for junctional adhesion molecule-A (JAM-A). The aim of the present study was to evaluate the effects of JAM-A and LFA-1 variants on the formation of colorectal cancer and metastasis